Monte Rosa Therapeutics, Inc.

Total Valuation

Monte Rosa Therapeutics, Inc. carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 561.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Monte Rosa Therapeutics, Inc. currently has 84.32M shares outstanding.

Valuation Ratios

Monte Rosa Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 37.04. The price-to-sales ratio is 27.66, and the price-to-book ratio stands at -2.28.

Enterprise Valuation

On an enterprise value basis, Monte Rosa Therapeutics, Inc. trades at an EV/EBITDA multiple of 7.58 and an EV/FCF ratio of 1.62. The EV/Sales ratio of 13.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.48 provides insight into valuation relative to core operating earnings.

Financial Position

Monte Rosa Therapeutics, Inc. maintains a current ratio of 9.54, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Monte Rosa Therapeutics, Inc.'s stock has gained approximately 282.32759% over the past 52 weeks. The 50-day moving average sits at 18.37, while the 200-day moving average is 15.07.

Income Statement

Over the trailing twelve months, Monte Rosa Therapeutics, Inc. generated 42.95M in revenue and converted that into -130.01M in net income, yielding earnings per share of -1.80. EBITDA reached -139.94M, while operating income came in at -148.28M.

Balance Sheet

Monte Rosa Therapeutics, Inc. holds 666.22M in cash and equivalents against 39.06M in total debt, resulting in a net debt position of -159.86M. Total book value stands at -521.71M, with working capital of 606.51M providing operational flexibility.

Cash Flow

Monte Rosa Therapeutics, Inc. produced -14.67M in operating cash flow over the past twelve months. After subtracting -4.98M in capital expenditures, free cash flow totaled -19.66M - equivalent to -0.27 per share.

Margins

Monte Rosa Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -345.21 and net profit margin of -302.69 provide insight into operational efficiency.

Dividends & Yields

Scores

Monte Rosa Therapeutics, Inc. posts an Altman Z-Score of 2.71, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.